Nov 4 (Reuters) - German drugmaker BioNTech

on Monday lowered its guidance for full-year revenue, citing

COVID-19 uptake and price levels, inventory write-downs and

Pfizer ( PFE ) charges.

The company now expects 2024 revenue to be at the low end of

the guidance range of 2.5 to 3.1 billion euros ($2.72 - $3.38

billion).

BioNTech, whose COVID-19 vaccine in partnership with Pfizer ( PFE )

was widely used during the pandemic, reported third-quarter

revenue of 1.24 billion euros compared to 895.3 million euros

year ago, helped by earlier approvals for its variant-adapted

COVID-19 vaccines.

In August, the Mainz-based company said some 90% of its

total research and development spending was going towards

non-COVID related activities, mainly oncology and mRNA.

"We remain focused on advancing our late-stage oncology

product candidates towards potential registration," said

BioNTech's CEO Ugur Sahin.

The company is aiming for its first oncology launch in 2026.

($1 = 0.9176 euros)